Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LRCUN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HuAb3v2.9-TX
|
|||||
| Synonyms |
huAb3v2.9 TX; huAb3v2.9TX
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.7
|
|||||
| Structure |
|
|||||
| Antibody Name |
huAb3v2.9
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
huAb3v2.9-TX linker
|
|||||
| Combination Type |
AbbVie's TX
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 86% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
|
||||
| In Vivo Model | H146 CDX model | ||||
| In Vitro Model | Small cell carcinoma | NCI-H146 cells | CVCL_1473 | ||